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The current data are still inconclusive in terms of a genetic component involved in the susceptibility to renal cell carcinoma.Our aim
was to evaluate 40 selected candidate polymorphisms for potential associationwith clear cell renal cell carcinoma (ccRCC) based on
independent group of 167 patients and 200 healthy controls. The obtained data were searched for independent effects of particular
polymorphisms as well as haplotypes and genetic interactions. Association testing implied position rs4765623 in the SCARB1 gene
(OR = 1.688, 95% CI: 1.104–2.582, 𝑃 = 0.016) and a haplotype in VDR comprising positions rs739837, rs731236, rs7975232, and
rs1544410 (𝑃 = 0.012) to be the risk factors in the studied population. The study detected several epistatic effects contributing
to the genetic susceptibility to ccRCC. Variation in GNAS1 was implicated in a strong synergistic interaction with BIRC5. This
effect was part of a model suggested by multifactor dimensionality reduction method including also a synergy betweenGNAS1 and
SCARB1 (𝑃 = 0.036). Significance of GNAS1-SCARB1 interaction was further confirmed by logistic regression (𝑃 = 0.041), which
also indicated involvement of SCARB1 in additional interaction with EPAS1 (𝑃 = 0.008) as well as revealing interactions between
GNAS1 and EPAS1 (𝑃 = 0.016), GNAS1 andMC1R (𝑃 = 0.031), GNAS1 and VDR (𝑃 = 0.032), andMC1R and VDR (𝑃 = 0.035).
1. Introduction
Kidney cancer is according to the International Agency for
Research on Cancer the third fastest increasing carcinoma
with the 30% growth noted in years 1993–2009. Clear cell
renal cell carcinoma (ccRCC) is themost often type of kidney
cancer in humans [1, 2]. Several factors including obesity,
hypertension, and smoking have been shown to increase risk
of developing renal cell carcinoma [3, 4]. It has also been
noted that this cancer is twice more frequent in males than
in females [5]. So far only few genes have been associated
with increased risk of RCC. The data obtained from three
genome wide association (GWA) studies performed on
European ancestry populations are inconsistent. First GWAS
revealed three loci located on 2p21, 11q13.3, and 12q24.31 to
be associated with RCC [6]. The gene EPAS1 located in the
region 2p21 has been previously suggested as a candidate
gene in RCC due to its overexpression in this carcinoma [7].
The region 12q24.31 contains the SCARB1 gene that encodes
receptor involved in uptake of high-density lipoprotein
cholesterol. Finemapping analysis of a 120 kb area nearEPAS1
has confirmed association of 2p21 region with RCC but
stronger signal was noted outside EPAS1 [8]. The second
GWAS has implicated the ITPR2 gene on 12p.11.23 as a novel
susceptibility locus for RCC while no other loci reached
genome-wide significance in this extended population sam-
ple [9].The thirdGWAstudy identified additional association
with RCC for ZEB2 gene encoding zinc finger E-box-binding
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homeobox 2 [10]. The recent GWAS conducted on samples
from African Americans has revealed the region 11q13.3
containing no genes to be associated with RCC, confirming
the outcome obtained before for Europeans [6, 11]. Other
loci implicated in RCC include GNAS1 showing a prognostic
value [12] and several genes which have been associated
with RCC risk. These latter ones include two genes from the
vitamin D pathway, namely, VDR and RXRA which encode
proteins forming a complex involved in vitamin D depen-
dent transcription regulation [13] and polymorphism in the
promoter of the VEGFA gene [14]. Two studies have reported
associations with RCC in Chinese population showing
polymorphism in the promoter of the BIRC5 gene [15] and
variation in the XRCC6 locus, to be the susceptibility can-
didates for renal cell carcinoma [16]. One study indicated
insertion/deletion polymorphism in the promoter region of
CASP8 encoding a key regulator of apoptosis, caspase-8, to be
a factor in RCC susceptibility and metastasis [17]. To fur-
ther investigate the problem of genetic susceptibility to
RCC we analysed 35 candidate polymorphisms within genes
previously implicated in RCC development and prognosis.
Additionally, 5 SNPs located in novel gene ZC3H12A encod-
ing MCP-1-induced protein (MCPIP1) involved in a regula-
tion of inflammatory reaction were included in the analyses.
MCPIP1 acts as an RNAse regulating stability of somemRNA
coding for proinflammatory cytokines and also regulates
activity of transcription factors, which are key regulators in
carcinogenesis (e.g., NF-𝜅B) [18–21]. Therefore, we hypothe-
size that variation inZC3H12Amaybe associatedwith the risk
of ccRCC development. Performed analyses included exam-
ination of main effects associated with all the selected 40
polymorphisms and the reconstructed haplotypes in EPAS1,
RXRA, and VDR as well as a thorough search for epistatic
effects using multifactor dimensionality reduction (MDR)
and logistic regression methods.
2. Materials and Methods
2.1. Study Population and Candidate Genetic Loci. This
research was approved by the bioethical commission of the
Regional Research Council in Kraków, number 68/KBL/OIL/
2011. All the subjects gave an informed consent. The study
sample comprised 167 ccRCC patients treated with a surgery
in the Centre of Oncology in Kraków and 200 healthy indi-
viduals frequency matched by sex and age. Tissues collected
from ccRCC patients were subjected to DNA extraction
using silica-based method with GeneJET Genomic DNA
Purification Kit (Thermo Fisher Scientific Inc., Waltham,
MA) using themanufacturer’s protocol. DNA from the buccal
swabs collected from the control groupwas extracted by silica
adsorption using the NucleoSpin Tissue extraction kit
(Macherey-Nagel GmbH & Co. KG, Germany) as previously
described [22]. Forty candidate polymorphisms including
eight SNPs previously associated with renal cell carcinoma
through the 4 genome wide association studies [6, 9–11] and
seven SNPs associated with RCC in the selected paramount
candidate gene approach association studies [12–17] were
included in the research. Additionally, nine most often inves-
tigated SNPs in the VDR gene were examined due to a sug-
gested association of this locus with RCC [13]. Eleven most
relevant SNPs in MC1R, which is the important melanoma
associated gene, were included due to a postulated increased
risk of RCC in melanoma patients [2]. The remaining 5 SNPs
are located in the ZC3H12A gene, which is involved in
regulation of inflammatory reaction [20]. Details on the
selected forty polymorphisms are given in Table 1.
2.2. Genotyping. Polymorphisms were genotyped in 5
multiplex and 1 singleplex PCR reactions. SNPs inmultiplexes
were amplified using Qiagen Multiplex PCR kit (Qiagen,
Hilden, Germany) and further analysed with single base
extension (SBE) reactions using SNaPshot Multiplex Kit
(Applied Biosystems, Foster City, CA). Multiplex 1 included
7 SNP positions (rs11894252, rs7579899, rs833061, rs3118523,
rs748964, rs7105934, and rs4765623), multiplex 2 consisted
of 6 SNPs (rs9679290, rs4953346, rs1049380, rs9904341,
rs7121, and rs132770), and multiplex 3 comprised further
6 SNPs (rs34796867, rs113322875, rs34031609, rs113655247,
rs17849897, and rs12105918). Sequences and concentrations of
PCR and SBE primers are shown in Supplementary Tables 1
and 2, respectively in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/860405. Amplifica-
tions were performed in 5 𝜇L reaction volume consisting of
2.5 𝜇L Qiagen Multiplex PCR mixture, 0.5 𝜇L of Q solution,
0.5 𝜇L of primer premix, and 1.5 𝜇L of template DNA.
The PCR reactions were carried out with the following
temperature profile: 95∘C/15min, [94∘/30 s, 58∘C/90 s,
72∘C/90 s] × 32, 72∘C/10min. The amplification products
were cleaned with a mixture (1 : 1) of Exonuclease I (Exo I)
and FastAPThermosensitive Alkaline Phosphatase (FastAP)
enzymes (Thermo Fisher Scientific Inc., Waltham, MA). The
minisequencing reactions consisted of 0.5 𝜇L of SNaPshot
mix, 0.5 𝜇L of SBE primer premix, 1 𝜇L of purified PCR
product, and 3𝜇L of DNase free water. The SBE temperature
profile was as follows: [96∘C/10 s, 50∘C/5 s, 60∘C/30 s] × 26.
Products of the extension reactions were purified with 1𝜇L
of FastAP Thermosensitive Alkaline Phosphatase enzyme
and analyzed with ABI 3100 Avant Genetic Analyser
(Applied Biosystems, Foster City, CA). The remaining 11
polymorphisms in MC1R (N29insA, rs1805005, rs1805006,
rs2228479, rs11547464, rs1805007, Y152OCH, rs1110400,
rs1805008, rs885479, and rs1805009) and 9 SNPs from the
VDR gene (rs739837, rs731236, rs7975232, rs1544410,
rs2228570, rs2238136, rs4516035, rs7139166, and rs11568820)
were analysed in additional two multiplexes using protocols
described elsewhere [22, 23].The remaining insertion/deletion
polymorphism in CASP8 was analysed in a single PCR
reaction using HotStarTaq Master Mix Kit (Qiagen, Hilden,
Germany) and following primer sequences 5󸀠-6-FAM-
AAACTTCTCCCATGGCCTCT-3󸀠 and 5󸀠-TATGAATGA-
GCCGAGGAAGG3󸀠. Amplificationswere carried out in 5 𝜇L
reaction volume consisting of 2.5 𝜇L HotStarTaqMaster Mix,
0.5 𝜇L of primer premix (concentration of 0.125𝜇M), 0.5 𝜇L
of distilled water, and 1.5 𝜇L of template DNA. The following
temperature profile was applied: 95∘C/15min, [94∘/30 s,
60∘C/45 s, 72∘C/60 s] × 30, 72∘C/10min. PCR products were
directly analyzed by capillary electrophoresis using ABI 3100
Avant Genetic Analyser (Applied Biosystems, Foster City,
CA).
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Table 1: Data for the studied 40 polymorphisms.
Locus Gene Chromosome Position (GRCh38) Allele variants MAF∗ Reference
rs34796867 ZC3H12A 1 37475773 C/T T = 0.000 [20]
rs113322875 ZC3H12A 1 37477383 G/A A = 0.000 [20]
rs34031609 ZC3H12A 1 37482928 G/A A = 0.000 [20]
rs113655247 ZC3H12A 1 37483276 G/C C = 0.000 [20]
rs17849897 ZC3H12A 1 37483451 C/T T = 0.014 [20]
rs12105918 ZEB2 2 144450626 G/A G = 0.051 [10]
rs11894252 EPAS1 2 46306237 C/T T = 0.356 [6]
rs7579899 EPAS1 2 46310465 C/T T = 0.357 [6]
rs9679290 EPAS1 2 46330505 G/C C = 0.451 [6]
rs4953346 EPAS1 2 46331069 C/A C = 0.452 [6]
rs3834129 CASP8 2 201232809:14 CTTACT/— Del = 0.450 [17]
rs833061 VEGFA 6 43769749 C/T C = 0.484 [14]
rs748964 RXRA 9 134442243 G/C G = 0.144 [13]
rs3118523 RXRA 9 134443675 G/A G = 0.202 [13]
rs7105934 11q13.3 11 69424973 C/T T = 0.040 [6]
rs1049380 ITPR2 12 26336611 G/T G = 0.436 [9]
rs739837 VDR 12 47844438 C/A A = 0.471 [13]
rs731236 VDR 12 47844974 G/A G = 0.354 [13]
rs7975232 VDR 12 47845054 G/T T = 0.469 [13]
rs1544410 VDR 12 47846052 C/T T = 0.361 [13]
rs2228570 VDR 12 47879112 G/A A = 0.456 [13]
rs2238136 VDR 12 47883930 G/A A = 0.365 [13]
rs4516035 VDR 12 47906043 C/T C = 0.458 [13]
rs7139166 VDR 12 47906551 G/C G = 0.454 [13]
rs11568820 VDR 12 47908762 C/T T = 0.128 [13]
rs4765623 SCARB1 12 124836304 G/A A = 0.361 [6]
N29insA MC1R 16 89919345 C/A A = 0.000 [2]
rs1805005 MC1R 16 89919436 G/T T = 0.078 [2]
rs1805006 MC1R 16 89919510 C/A A = 0.001 [2]
rs2228479 MC1R 16 89919532 G/A A = 0.108 [2]
rs11547464 MC1R 16 89919683 G/A A = 0.007 [2]
rs1805007 MC1R 16 89919709 C/T T = 0.040 [2]
Y152OCH MC1R 16 89919714 C/A A = 0.000 [2]
rs1110400 MC1R 16 89919722 C/T C = 0.026 [2]
rs1805008 MC1R 16 89919736 C/T T = 0.068 [2]
rs885479 MC1R 16 89919746 C/T T = 0.035 [2]
rs1805009 MC1R 16 89920138 G/C C = 0.001 [2]
rs9904341 BIRC5 17 78214286 G/C C = 0.343 [15]
rs7121 GNAS1 20 58903752 C/T T = 0.465 [12]
rs132770 XRCC6 22 41621260 G/A A = 0.153 [16]
∗MAF = minor allele frequency.
2.3. Statistical Analyses
2.3.1. Population Analyses and Haplotype Reconstruction.
Genetic data obtained for the 40 selected polymorphisms
were tested for deviations fromHardy-Weinberg equilibrium.
Hardy-Weinberg analysis was performed with Arlequin ver-
sion 3.1 software (http://cmpg.unibe.ch/software/arlequin3/).
Haploview version 4.2 software was used to test the degree
of linkage disequilibrium among DNA variants in EPAS1,
RXRA, andVDR (http://www.broadinstitute.org/).Haplotype
reconstruction and frequency estimation were done for SNPs
located in EPAS1, RXRA, and VDR using PHASE version
2.1 computer software (http://stephenslab.uchicago.edu/soft-
ware.html#phase). Haplotype reconstruction and LD anal-
ysis did not include polymorphisms in the MC1R gene
because they all may individually affect receptor performance
[24] and polymorphisms in ZC3H12a as besides one SNP
(rs17849897) they turned out to be monomorphic in the
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tested population. In the case of VDR gene, polymorphisms
were divided into 3 blocks following the obtained results and
literature suggestions [25, 26]. Positions rs739837, rs731236,
rs7975232, and rs1544410 were included in the first block.The
second block was formed by a single rs2228570 posi-
tion whereas in the third block the remaining rs2238136,
rs4516035, rs713966, and rs11568820 positions were con-
sidered. Minimal ORs detectable with the power of at least
80% were calculated with Power and Sample Size Program
(PS Program) version 3.1.2 (http://biostat.mc.vanderbilt.edu/
wiki/Main/PowerSampleSize).
2.3.2. Association Testing. Univariate associations between
single selected polymorphisms and ccRCC status were
assessed through binary logistic regressionwith PASW statis-
tics version 21 computer software (SPSS Inc., Chicago, IL,
USA). Odds ratios (ORs) with corresponding 95% confi-
dence intervals (CIs) and 𝑃 values were assigned. Additive,
recessive, and dominant models of allele categorization were
tested. In case of the MC1R gene, polymorphisms were
divided in two groups according to their known influence
on pigmentation phenotype. Strong variants marked with
“𝑅” (N29insA, rs1805006, rs1805007, rs11547464, rs1805008,
rs1805009, and Y152OCH) have been considered as high-
penetrance since they significantly diminish the receptor
performance and have strong phenotypic effect (OR values
of ∼50 or higher). Weak variants marked with “𝑟” are low-
penetrance and have weaker effect on the receptor perfor-
mance and therefore weaker phenotypic effect (OR below ∼
10). Such a categorization has been applied in several previous
studies (e.g., [27]). For “𝑅” variants, three states were consid-
ered according to the existence of major function mutations
(0 = no “𝑅” variant carriers, 1 = one “𝑅” variant carriers, and
2 = two “𝑅” variant carriers) and the same approach was used
in case of “𝑟” variants. Binary logistic regression was also
used to evaluate the association of the inferred haplotypes
(with frequency exceeding 0.5%) under the assumption
of additive inheritance mode. Association analyses were
conducted considering 𝑃 value of <0.05 level as statisti-
cally significant; however associations were also tested with
false discovery rate (FDR) correction for multiple compar-
isons (http://www.seu.ac.lk/cedpl/student download/Benja-
miniHochberg.xlsx). Finally, multivariate logistic regression
was applied including simultaneous analysis of all the poly-
morphisms and haplotypes as well as disclosed interactions.
2.3.3. Epistasis Examination. Statistical locus-locus inter-
actions were examined using two methods, that is, multi-
factor dimensionality reduction (MDR v2.0 beta 8.1
http://www.epistasis.org/) and binary logistic regression
(PASW statistics v.21). MDR approach enables evaluation of
epistatic effects through assignment of all genotype combi-
nations between interacting loci to one of the two groups:
“high-risk” or “low-risk” of disease development based on
the ratio of cases to controls and the analysis is performed as
described elsewhere [28]. The results of MDR analysis were
interpreted using entropy-based approach which is a
nonparametric method for estimation of the benefit in
information gain from interaction between two analyzed
attributes [29]. In addition to MDR analysis, the parametric
binary logistic regression method was applied. Pairwise
interactions were tested by introducing interaction terms
into the two-factor logistic regression models using forward
selection strategy. ORs with 95% CIs and respective 𝑃 values
were estimated for interactions disclosed with logistic
regression.
2.3.4.Meta-Analysis. Meta-analysis for rs4765623 in SCARB1
was performed with MetaEasy v1.0.5 [30] and involved data
from our population and data for three different sample sets
(IARC, NCI, Replication) from the study of Purdue et al.
(2011) [6]. OR value for the combined data was calculated
with the fixed effects model and 𝑃 value was estimated
based on 95% CI with the method described in Altman and
Bland [31]. Heterogeneity was investigated using Cochrane Q
𝑃 value and 𝐼2 statistics which assessed the consistency in
meta-analysis studies. 𝐼2 ranges from 0% to 100% where 0%
indicates no heterogeneity whereas increasing value of 𝐼2
indicates increasing level of heterogeneity.
3. Results
3.1. Population Analyses and Haplotype Inference. No signif-
icant departures from the Hardy-Weinberg equilibrium were
noted after Bonferroni’s correction for multiple testing (𝑃 >
0.0013) for the examined loci. Results of LD analysis among
DNA variants investigated in EPAS1, RXRA, and VDR are
presented in Supplementary Figure 1. Two haplotype blocks
(rs11894252-rs7579899; rs9679290-rs4953346) with strong
LD (𝑟2 > 0.9) were found in the EPAS1 gene, moderate
linkage disequilibrium was revealed for two SNPs rs748964-
rs3118523 (𝑟2 = 0.65) in the RXRA gene whereas in the VDR
gene strong linkage for two SNPs rs4516035-rs7139166 (𝑟2 >
0.9) and 4 SNPs-haplotype block comprising rs739837-
rs731236-rs7975232-rs1544410 (𝑟2 > 0.5) were detected. From
7 haplotypes reconstructed with PHASE program for all
SNPs in EPAS1, 4 were very frequent. In case of RXRA 3
frequent and 1 rare haplotypes were reconstructed. In the
block number 1 in VDR, comprising 4 SNPs, 10 haplotypes
were reconstructed but only 6 were found to have frequency
above 0.5%. In case of block number 3 in VDR 11 haplotypes
were reconstructed with 7 exceeding the 0.5% threshold. The
reconstructed haplotypes and their frequencies are listed in
Supplementary Table 3.
3.2. Association and Interaction Analyses. Samples collected
from patients and controls were frequency matched by sex
(58.1% of males in the ccRCC group and 51% in the control
group) and age (the mean age of the participants was 64
years in the ccRCC group and 62 years in the control group).
Univariate analyses performed for the particular 40 poly-
morphisms under study revealed rs4765623 in the SCARB1
gene to be associated with ccRCC in our population but only
considering dominant mode of inheritance (𝑃 = 0.016) and
this result did not pass FDR procedure. According to logistic
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Table 2: Results of multifactor dimensionality reduction analysis performed for ccRCC status.
Multifactor dimensionality reduction analysis
Best candidate model
(for up to five factor combinations) BA
∗ CVC∗∗ 𝑃-value∗∗∗
rs4765623 0.5469 10/10 0.244
rs4765623; rs4953346 0.5125 4/10 0.658
rs4765623; rs4953346; rs9904341 0.5319 5/10 0.432
rs4765623; rs4953346; rs9904341; rs7121 0.5828 10/10 0.036
rs4765623; rs4953346; rs9904341; rs7121; rs132770 0.5598 10/10 0.140
Best model is marked with bold.
∗BA: balanced accuracy.
∗∗CVC: cross-validation consistency.
∗∗∗Permutation testing 𝑃 value.
regression analysis individuals with at least one minor A
allele have 1.7 higher odd of ccRCC development comparing
to individuals with GG genotype (OR = 1.7, 95% CI: 1.104–
2.582). Additive mode of allele inheritance did not reach
the threshold of 0.05 significance (𝑃 = 0.075). Except for
rs4765623 in SCARB1 no other SNP showed main effect in
our study. We also could not verify significance of 4 SNPs in
the ZC3H12a gene which were found to be monomorphic in
this sample set. The only polymorphic position in ZC3H12a
(rs17849897) with the minor allele frequency of 1.4% turned
out not to be associated with ccRCC. Results of univariate
association analyses are provided in Supplementary Table 4.
An association testing performed for the reconstructed
haplotypes revealed thatCAGThaplotype inVDR gene (com-
prising rs739837-rs731236-rs7975232-rs1544410) observed
with frequency 0.68% might be a risk factor for ccRCC (𝑃 =
0.012). This result was also found to be insignificant after
applying the FDR procedure. Notably, however, CAGT
haplotype was observed in 5 among 167 cases of ccRCC but
was completely absent in the control group of 200 individuals.
Haplotypes reconstructed in the EPAS1 and RXRA did not
reveal any association with ccRCC under the significance
threshold of 0.05.
The study revealed several epistatic effects involving
the abovementioned DNA variants in SCARB1 and VDR,
which confirmed suggestive association trends with ccRCC.
According to MDR analysis, ccRCC is best explained by the
four-factor model comprising rs4765623 in SCARB1,
rs4953346 inEPAS1, rs9904341 inBIRC5, and rs7121 inGNAS1
with balanced accuracy (BA) of 0.5828, cross-validation
consistency (CVC) of maximum level 10/10, and permutation
testing 𝑃 value of 0.036 (Table 2). Analysis of interaction
dendrogram provided by MDR confirmed implication of
these factors in epistatic effects showing strong positive
(synergistic) interactions between rs7121 in GNAS1,
rs9904341 in BIRC5, and rs4765623 in SCARB1 (Figure 1).
Entropy-based interaction graph confirmed strong positive
effects between rs7121 and rs9904341 and between rs7121
and rs4765623. According to the entropy-based analysis the
largest main effect is attributed to rs4765623 in SCARB1. This
position removes 1.28% of entropy, what is understood to
remove 1.28% of “uncertainty” in prediction of ccRCC status.





Figure 1: Interaction dendrogram provided with MDR analysis.
Dendrogram interaction graphs are built using hierarchical cluster
analysis and illustrate the presence, strength, and nature of epistatic
effects. The more the line connecting two factors is moved to the
right side, the stronger the interaction effect is.The red line between
factors indicates a high degree of synergy whereas the orange line
indicates a lesser degree of synergy.
whereas the interaction between these two factors removes
additional 0.55% of entropy which is not removed by any
of these factors treated individually. In case of the second
interaction revealed, between rs7121 inGNAS1 and rs9904341
in BIRC5 positive value of entropy brought by interaction
equaled 0.62% which indicates additional benefit in
information gain when considering epistasis between these
factors (Figure 2).
Pairwise interaction testing performed with logistic
regression confirmed significance of rs4765623-rs7121 inter-
action (𝑃 = 0.041) and revealed 5 additional epistatic effects
(Table 3). The highest statistical significance was noted for
interaction between rs4765623 in SCARB1 and rs9679290 in
EPAS1 (𝑃 = 0.008). Statistical significance was also noted for
interaction between rs7121 inGNAS1 and rs9679290 in EPAS1
(𝑃 = 0.016). The remaining interactions of potential influ-
ence on ccRCC include GNAS1–MC1R (𝑃 = 0.031), GNAS1–
VDR (𝑃 = 0.032), and MC1R-VDR (𝑃 = 0.035). Overall,
6 genes (SCARB1, GNAS1, EPAS1, BIRC5, MC1R, and VDR)
were found to be implicated in interaction effects of potential
influence on ccRCC development (Table 3).
Finally, multivariate logistic regression involving simulta-
neous analysis of all the studied polymorphisms, haplotypes,
and gene-gene interactions revealed the following factors to
be relevant in susceptibility to ccRCC: CAGT haplotype in
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Table 3: Interaction effects of statistical significance in ccRCC development revealed with binary logistic regression analysis.




rs4765623∗rs9679290 SCARB1∗EPAS1 1.371 (1.087–1.729) 0.008
rs7121∗rs9679290 GNAS1∗EPAS1 1.284 (1.047–1.575) 0.016
rs7121∗rs1805008 GNAS1∗MC1R 2.601 (1.089–6.212) 0.031
rs7121∗rs2228570 GNAS1∗VDR 1.240 (1.018–1.510) 0.032
MC1R “r”∗rs7975232 MC1R∗VDR 1.341 (1.020–1.763) 0.035
rs7121∗rs4765623 GNAS1∗SCARB1 1.639 (1.020–2.639) 0.041
Table 4: Results of multivariate binary logistic regression analysis concerning all SNPs under study, haplotypes, and disclosed interactions.
Multivariate binary logistic regression analysis
Variables in the model Genes OR (95% CI) 𝑃 value of variablein the model
Haplotype CAGT (rs739837-rs731236-rs7975232-rs1544410) VDR cs 0.005
rs4765623∗rs9679290 SCARB1∗EPAS1 1.389 (1.094–1.763) 0.007
MC1R “r”∗rs7975232 MC1R∗VDR 1.455 (1.095–1.933) 0.010














Figure 2: Entropy-based interaction radial graph provided with
MDR analysis. Entropy values in the cells of individual factors
indicate the main independent effects whereas the entropy values
marked on the lines connecting two factors represent the effect of
interaction.
VDR (𝑃 = 0.005), interaction between rs4765623 in SCARB1
and rs9679290 in EPAS1 (𝑃 = 0.007), interaction between
variants “𝑟” inMC1R and rs7975232 in VDR (𝑃 = 0.010), and
interaction between rs7121 in GNAS1 and rs2228570 in VDR
(𝑃 = 0.041) (Table 4).This final logistic regression model has
the significance of 𝜒2 𝑃 = 6.98 × 10−6 and explains 9.2% of
the total risk in ccRCC development.
3.3. Results of Meta-Analysis. Meta-analysis of the pooled
data from Purdue et al. [6] and the results of our study for
rs4765623 in SCARB1 indicated that moderate heterogeneity
may be present among the tested population samples with
𝐼
2
= 62.10% and Cochrane Q 𝑃 value = 0.048. Effect size of
rs4765623 in SCARB1 calculated for the combined data was
OR = 1.145, 95% CI: 1.093–1.200 with 𝑃 = 2.483 × 10−8.
4. Discussion
The picture arising from the available genetic data for renal
cell carcinoma is ambiguous with no single polymorphism
showing a record of repeatable and reliable association with
RCC in independent studies. Here, we analyzed a group of
167 ccRCC patients and 200 healthy controls examining 40
candidate polymorphisms in 14 loci selected from the litera-
ture [2, 6, 9, 10, 12–19].
The study revealed rs4765623 in the SCARB1 gene to
show association trend with ccRCC in the studied population
sample. The SCARB1 gene encodes the scavenger receptor
class B member 1 which binds to the high-density lipoprotein
(HDL) cholesterol and thereforemediates cellular cholesterol
homeostasis. Cholesterol transfer towards liver for excretion
is known as a protective mechanism against the development
of atherosclerosis [32]. The role of SCARB1 in cancer biology
is not well investigated but it has been recently suggested that
SCARB1 receptor may be involved in multiple functions [33]
and that cholesterol entry through SCARB1-HDL can activate
signal transduction pathways that can regulate cellular pro-
liferation and migration and therefore carcinogenesis [34].
Association of rs4765623 position in SCARB1 with RCC
was first identified in GWAS study performed on European
population by Purdue et al. in 2011 [6].The revealed effect was
weak (OR = 1.15) but significant (𝑃 = 2.6 × 10−8). How-
ever, this association has not been confirmed in replication
studies performed on Chinese population [35, 36]. Our
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results confirmed association of the rs4765623 minor allele
A (𝑓 = 36.1%) with susceptibility to ccRCC in European
(Polish) population sample and can serve as an independent
replication to further establish the association for rs4765623
for renal cell carcinoma risk.The effect identified in our study
(OR = 1.7) was stronger than in the study of Purdue but this
value was observed when dominant mode of minor allele
classification was applied. Frequency of A risk allele reported
in Purdue et al. was similar to our study (34%). Purdue et
al. has reported significant heterogeneity for rs4765623 in
SCARB1 (𝑃 = 0.03) among the three studied groups [6].
Meta-analysis including our data also suggests moderate
interpopulation heterogeneity with ∼62% 𝐼2 value but the
significance decreased from 0.03 to 0.048. The effect size of
rs4765623 in SCARB1 for the combined data, including our
population, was very similar to that obtained in Purdue et al.
(OR = 1.145, 𝑃 = 2.483 × 10−8).
Our study also revealed suggestive association trend of
VDR haplotype comprised of four SNPs, namely, rs739837,
rs731236, rs7975232, and rs1544410, with ccRCC risk. VDR
gene encodes vitaminD receptorwhich is involved in vitamin





considered to be a protective factor against cancer develop-
ment due to its role in cell growth regulation, differentiation,
programmed cell death, angiogenesis, and moderation of
gene transcription [37, 38]. Indeed, several functional studies
have shown that the level of the active form of vitamin D is
significantly lower in ccRCC patients than in healthy controls
[39, 40]. The active form of vitamin D binds to the vitamin
D receptor which is predicted to regulate expression of over
2000 genes in humans [41]. Notably, variation in VDR gene
has been implicated in many carcinomas (e.g., [13, 42–47]).
However, few reports are available on association between
VDR polymorphism and renal cell carcinoma and the
obtained results are inconsistent [48, 49]. Most of the pre-
vious studies have been performed on Asian populations
[50, 51] and recent meta-analyses showed that association of
VDR polymorphism with ccRCC may be population specific
[52, 53]. Polymorphisms included in the haplotype associated
with ccRCC in our study are located in the 3󸀠 region of VDR
gene and are supposed to influence mRNA level [54]. Allele
T of rs731236 (TaqI) polymorphism was associated with
increased risk of RCC in a Japanese population sample [50]
and then confirmed in a population of European descent [13].
However, several other studies have not confirmed that
association (e.g., [51]). Our research revealed increased risk of
RCC development associated with allele T in rs731236 when
considered in the haplotype with three other SNPs. Interest-
ingly, the identified risk haplotype CAGT was absent in a
group of 200 healthy controls. Moreover, we analysed VDR
variation in additional 300 controls and did not observe this
haplotype (𝑃 = 0.008, data not shown). Association of a
haplotype in the VDR gene with RCC was also noted by
Karami et al. but in that study different region of the VDR
gene was involved [13].
The discovered main association effects need to be inter-
preted as trends only because they did not pass FDR pro-
cedure. Small number of samples was an obvious limitation
of this study that could prevent detection of weak genetic
effects known to be typical for ccRCC. However, non-
replication may have also been caused by interpopulation
heterogeneity [55] which was observed in meta-analysis for
rs4765623 in SCARB1. Our sample size was sufficient to detect
the true effects of OR = 1.803–1.941 (depending on minor
allele frequency) with 80% probability for 19 out of 40 tested
DNA variants. Among variants associated with RCC through
GWA studies the strongest effect has been shown so far for
rs7105934 (11q13.3) with OR equaling 1.41 in European sam-
ples [6] and 1.79 in African American samples [11]. It seems
therefore that most of the known genetic RCC risk factors
might have escaped detection in this study. However, besides
main effects of the studied loci we also used statistical meth-
ods to test interactions between them. Notably, the SCARB1
locus was implicated by the MDR method in complex gene-
gene interactions in the studied population sample. The sig-
nificance of epistasis in the determination of complex traits is
currently often emphasized and it has been suggested that the
impact of genetic interactions may even outrank an indepen-
dentmain effect of single susceptibility loci [56]. Importantly,
the applied MDR approach was developed as nonparametric
and genetic model-free data mining strategy for epistasis
identification in studies dealing with relatively small sample
size [28, 57]. It has been postulated that this method is less
prone to I type error and thus more reliable than logistic
regression. MDR showed that four-factor model compris-
ing two synergistic interactions, the first between rs7121
in GNAS1 and rs9904341 in BIRC5 and the second between
rs7121 inGNAS1 and rs4765623 in SCARB1, best explains sus-
ceptibility to ccRCC. The GNAS1 gene encodes a 𝛼s subunit
of heterotrimeric G protein that is required for activation
of adenylyl cyclase and generation of cAMP and plays the
key role in multiple signal transduction pathways, linked to
proapoptotic processes in cancer cells. Modulated expression
of this gene has been associated with various disorders
(e.g., [58, 59]). GNAS1 has been linked to RCC in two
independent studies [12, 60]. The BIRC5 gene encodes sur-
vivin, a protein preventing apoptotic cell death. Overexpres-
sion of this gene has a continuous literature record of its
prognostic significance in many carcinomas (e.g., [61, 62]).
Increased expression of survivin has also been reported in
RCC [63]. Recently, promoter mutation rs9904341 in BIRC5
has been associated with susceptibility to RCC in Asians [15].
There is evidence that this polymorphism regulates tran-
scriptional activity increasing survivin level [64]. Notably,
there are evidences that there is a direct dependency between
GNAS1 and BIRC5 products. Subunit 𝛼s activates STAT3
transcription factor inducing signal through the PKA kinase,
JNK, andPI3K [65]. In turn, STAT3 is important in activation
of survivin encoded by BIRC5 gene (e.g., [66]). Therefore,
synergistic interaction of GNAS1 and BIRC5 in susceptibility
to ccRCC discovered in this study seems to be justified. In
one of the recent studies utilizing ccRCC data provided by
the Cancer Genome Atlas (TCGA), another member of the
same group of inhibitors of apoptosis BIRC7 has been listed
among genes differentially expressed in ccRCC [67]. The
MDRmethod also revealed that rs7121 inGNAS1 is also impli-
cated in synergistic interaction with rs4765623 in SCARB1.
This interaction was further confirmed by logistic regression
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(𝑃 = 0.041). Interestingly, logistic regression also revealed
additional and more statistically significant epistatic effect
with SCARB1 as a component, that is, interaction between
rs4765623 in SCARB1 and rs9679290 in EPAS1 (𝑃 = 0.008).
Although a direct dependency between EPAS1 and SCARB1
or their protein products is unclear, it is worth noting that
both these loci are related to the processes connected with
angiogenesis. The SCARB1 gene, as it was mentioned before
encodes receptor that binds to the high-density lipoprotein
(HDL). It has been suggested that beyond its best known
function in cholesterol mediation, HDL is also involved in
many different activities like anti-inflammatory, antiapop-
totic processes and a variety of endothelial behaviors and
therefore angiogenesis (e.g., [68, 69]). The second locus
involved in the revealed interaction is EPAS1 which was
associated with ccRCC in a large GWA study performed by
Purdue et al. [11]. This gene encodes a hypoxia-inducible
factor 2 (HIF2𝛼) which belongs to the transcription factors
responsible for induction of genes controlled by oxygen.
Under normal conditions, the level of HIFs is regulated
by ubiquitinase complex, comprising a von Hippel-Lindau
tumor suppressor protein (pVHL). In normoxia HIF factors
are ubiquitinated and degraded. With a drop of oxygen level
(e.g., in tumors), stabilization of HIF1𝛼 and HIF2𝛼 (encoded
by EPAS1) occurs, which is what results in induction of
transcription of many genes encoding proteins involved in
angiogenesis [70]. Inactivation of VHL gene is observed in
approximately 90% of patients with clear cell RCC and
leads to accumulation of HIF1𝛼 and HIF2𝛼 proteins and in
consequence to stimulation of expression of protooncogenes
TGF𝛼 and c-Met [7, 71, 72].
The GNAS1 gene was found in our study to be implicated
in other epistatic effects with MC1R (𝑃 = 0.031), EPAS1
(𝑃 = 0.016), and VDR (𝑃 = 0.032). The MC1R gene encodes
melanocortin 1 receptor which is involved in the regulation
of melanin pigment synthesis which has also been found
to increase the risk of developing melanoma (e.g., [44, 73,
74]). It is well established that patients with cancer are at
higher risk to develop multiple cancers and some examples
of melanoma and RCC coexistence have been reported (e.g.,
[75, 76]). However, risk factors common for both cancers are
only partially explained and include mutations inMITF gene
[77]. Interestingly, product of MC1R gene acts through G-
protein. Therefore, there is a direct molecular dependence
betweenMC1R andGNAS1 products. Importantly, it has been
demonstrated that MC1R is expressed in the kidney cells
and shown that treatment with MC1R agonists ameliorated
kidney diseases in rats with passive Heymann nephritis [78].
Finally, logistic regression also indicated interaction between
theMC1R andVDR genes (𝑃 = 0.035). It is not clear how this
epistatic effect could affect ccRCC development, but interac-
tion between these two genes has been suggested to influence
human pigmentation [23, 79]. Interestingly, in the recent
TCGA study another gene involved in melanogenesis and
increased risk of melanoma that is the TYRP1 locus [74] has
been selected as differentially expressed in ccRCC [67]. The
overlap between risk factors in melanoma and ccRCC seems
to be interesting and worth further investigation.
In conclusion, position rs4765623 in SCARB1 and hap-
lotype in VDR showed suggestive association trends with
ccRCC susceptibility in the studied Polish population. More-
over using MDR and logistic regression methods, a com-
plex network of interactions involving six genes previously
implicated in RCC (SCARB1, GNAS1, BIRC5, EPAS1, VDR,
and MC1R) was discovered. Due to a relatively small sample
number these epistatic effects should be further studied and
confirmed on a larger cohort. The risk haplotype in VDR
and the gene-gene interactions SCARB1-EPAS1,GNAS1-VDR,
andMC1R-VDR were included in the final logistic regression
model explaining 9.2% of the total risk in ccRCC develop-
ment.
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